Investigation on superconducting and magnetic levitation force behaviour of excess Mg doped-bulk MgB2 superconductors

GUNER, SAIT BARIS/0000-0001-7487-4817; Ozturk, Kemal/0000-0002-8847-1880WOS: 000483647500017A series bulk samples of MgB2 + x wt% of Mg (x = 0, 5, 10, 15, 20 and 30) were fabricated by solid state reaction method. the structural and electromagnetic properties of MgB2 samples were studied using X-ray diffraction (XRD), scanning electronic microscope (SEM), electrical resistivity (R-T), magnetic hysteresis (M-H), magnetic levitation (F-z) force and lateral force (F-x) measurements. the maximum repulsive and attractive force values of 15 wt% of excess magnesium MgB2 sample compared to the other samples imply that the intergranular connection between grains enhanced while pore and microcrack density decreased which brings an increase in the values of the radius of a shielding current loop (r) and the critical current density (J(c)). It was determined that to obtain the enhancement of the micro and macro structure properties, causing to the higher critical current density, and the maximum levitation and lateral force values, the optimum excess magnesium content was 15 wt % into sample. It is thought that an addition of 10-15% excess magnesium can be tried for spark plasma or other methods -as a further research- and the results showed a potential to guide the researchers to study on the material-fabrication and the magnetic bearing system.Karadeniz Technical University Scientific Research Projects Coordination DepartmentKaradeniz Technical University [FBA-2016-5450]; Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [110T622, 2013/13638]This research was supported by Karadeniz Technical University Scientific Research Projects Coordination Department. Project Number: FBA-2016-5450. All the magnetic levitation force measurements were carried out in the MLFMS made by the project of the Scientific and Technological Research Council of Turkey (TUBITAK) Project NSo: 110T622 (Patent application number is 2013/13638)

Serum procalcitonin and C-reactive protein kinetics as indicators of treatment outcome in hospitalized patients with community-acquired pneumonia

WOS: 000389053000023PubMed ID: 27966308Background/aim: There has been growing interest in the use of serum procalcitonin (PCT) and C-reactive protein (CRP) in patients with community-acquired pneumonia (CAP). The aim of this study was to investigate whether an assessment of fever, leukocyte count, and serum CRP and PCT levels on admission and during follow-up (day 3) provides any information about the clinical outcome in hospitalized patients with CAP. Materials and methods: Patients with a diagnosis of CAP who were admitted to and followed at four university hospitals were evaluated retrospectively using the Turkish Thoracic Society Pneumonia Database. Results: A total of 103 hospitalized CAP patients (57 males, mean age: 61.5 +/- 16.7 years) were enrolled in the study. Treatment failure (TF) was observed in 20 patients (19.4%). Pneumonia Severity Index scores, serum CRP levels, and PCT levels on admission were significantly higher in the TF group. There were significant decreases in CRP and PCT levels between admission day and day 3 in the treatment success group. Conclusion: In patients with CAP, the body temperature and leukocyte count on admission do not predict outcome. Monitoring levels of CRP and PCT may be useful as a predictor of treatment outcome

Factors affecting treatment success in community acquired pneumonia (CAP)

WOS: 00020937040245

Community-acquired pneumonia in patients with chronic obstructive pulmonary disease requiring admission to the intensive care unit: Risk factors for mortality

Conclusion: Noninvasive ventilation, hypertension, systemic corticosteroid treatment, and shorter ICU stay are associated with reduced mortality, whereas bilateral infiltration and longer duration of invasive mechanical ventilation are associated with increased risk of mortality in patients with COPD and CAP requiring ICU admission. (C) 2013 Elsevier Inc. All rights reserved